Portola Pharmaceuticals Company Profile (NASDAQ:PTLA)

About Portola Pharmaceuticals (NASDAQ:PTLA)

Portola Pharmaceuticals logoPortola Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients having limited or no approved treatment options. The Company's two lead programs, Betrixaban and Andexanet alfa, address unmet medical needs in the area of thrombosis, or blood clots. Its third product candidate is Cerdulatinib. The Company's Syk is a mediator of immune response in various types of immune cells. The Company has a program of selective Syk inhibitors, one of which is partnered with Ora Inc. Betrixaban is an oral once-daily inhibitor of Factor Xa in development for extended duration venous thromboembolism (VTE) prophylaxis in acute medically ill patients. Andexanet alfa is an orphan drug, which is a recombinant protein designed to reverse anticoagulant activity in patients treated with an fXa inhibitor.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: N/A
  • Symbol: NASDAQ:PTLA
  • CUSIP: N/A
  • Web: www.portola.com
Capitalization:
  • Market Cap: $2.92 billion
  • Outstanding Shares: 57,662,000
Average Prices:
  • 50 Day Moving Avg: $54.70
  • 200 Day Moving Avg: $49.75
  • 52 Week Range: $15.68 - $67.10
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -27.83
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $31.93 million
  • Price / Sales: 91.47
  • Book Value: $1.93 per share
  • Price / Book: 26.24
Profitability:
  • EBITDA: ($251,010,000.00)
  • Net Margins: -807.93%
  • Return on Equity: -145.12%
  • Return on Assets: -78.93%
Debt:
  • Debt-to-Equity Ratio: 0.90%
  • Current Ratio: 4.95%
  • Quick Ratio: 4.95%
Misc:
  • Average Volume: 951,786 shs.
  • Beta: 1.27
  • Short Ratio: 4.37
 

Frequently Asked Questions for Portola Pharmaceuticals (NASDAQ:PTLA)

What is Portola Pharmaceuticals' stock symbol?

Portola Pharmaceuticals trades on the NASDAQ under the ticker symbol "PTLA."

How were Portola Pharmaceuticals' earnings last quarter?

Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) issued its quarterly earnings results on Wednesday, August, 9th. The company reported ($1.22) earnings per share for the quarter, missing the Zacks' consensus estimate of ($1.10) by $0.12. The company earned $3.79 million during the quarter, compared to analysts' expectations of $4.28 million. Portola Pharmaceuticals had a negative return on equity of 145.12% and a negative net margin of 807.93%. The company's revenue for the quarter was down 10.4% compared to the same quarter last year. During the same period in the prior year, the business posted ($1.02) EPS. View Portola Pharmaceuticals' Earnings History.

When will Portola Pharmaceuticals make its next earnings announcement?

Portola Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, November, 6th 2017. View Earnings Estimates for Portola Pharmaceuticals.

Where is Portola Pharmaceuticals' stock going? Where will Portola Pharmaceuticals' stock price be in 2017?

8 equities research analysts have issued twelve-month price objectives for Portola Pharmaceuticals' stock. Their predictions range from $27.00 to $81.00. On average, they expect Portola Pharmaceuticals' stock price to reach $67.67 in the next twelve months. View Analyst Ratings for Portola Pharmaceuticals.

What are analysts saying about Portola Pharmaceuticals stock?

Here are some recent quotes from research analysts about Portola Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "Portola Pharmaceuticals, Inc. is a biopharmaceutical company .It focuses on the development and commercialization of therapeutics for thrombosis, other hematologic disorders and inflammation. Portola Pharmaceuticals, Inc. is headquartered in South San Francisco, California. " (8/8/2017)
  • 2. Cowen and Company analysts commented, "Portola hosted an investor event at the American College of Cardiology (ACC) annual meeting. Data from betrixaban's APEX Phase III and AndexXa's ANNEXA-4 Phase IV trials were discussed. Investors were keenly focused on examining the APEX clinical data ahead of betrixaban's June PDUFA. While risk remains, we think approval is more likely than not. We remain at Outperform." (3/20/2017)

Who are some of Portola Pharmaceuticals' key competitors?

Who are Portola Pharmaceuticals' key executives?

Portola Pharmaceuticals' management team includes the folowing people:

  • Hollings C. Renton III, IndependentChairman of the Board
  • William Lis, Chief Executive Officer, Director
  • Mardi C. Dier, Chief Financial Officer, Executive Vice President
  • John T. Curnutte M.D. Ph.D., Executive Vice President - Research & Development
  • Tao Fu, Executive Vice President, Chief Commercial and Business officer
  • Jeffrey W. Bird M.D. Ph.D., Independent Director
  • Laura A. Brege, Independent Director
  • Dennis M. Fenton Ph.D., Independent Director
  • Charles J. Homcy M.D., Independent Director
  • John H. Johnson, Independent Director

Who owns Portola Pharmaceuticals stock?

Portola Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include Fisher Asset Management LLC (0.11%). Company insiders that own Portola Pharmaceuticals stock include (Mauritius) Pte Ltd Maxwell, Charles J Homcy, Fullerton Management Pte Ltd, Jeffrey W Bird, John T Curnutte, Mardi Dier, Tao Fu and William Lis. View Institutional Ownership Trends for Portola Pharmaceuticals.

Who bought Portola Pharmaceuticals stock? Who is buying Portola Pharmaceuticals stock?

Portola Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including Fisher Asset Management LLC. Company insiders that have bought Portola Pharmaceuticals stock in the last two years include Fullerton Management Pte Ltd and Jeffrey W Bird. View Insider Buying and Selling for Portola Pharmaceuticals.

How do I buy Portola Pharmaceuticals stock?

Shares of Portola Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Portola Pharmaceuticals' stock price today?

One share of Portola Pharmaceuticals stock can currently be purchased for approximately $50.65.


MarketBeat Community Rating for Portola Pharmaceuticals (NASDAQ PTLA)
Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  231 (Vote Outperform)
Underperform Votes:  130 (Vote Underperform)
Total Votes:  361
MarketBeat's community ratings are surveys of what our community members think about Portola Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Portola Pharmaceuticals (NASDAQ:PTLA) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating, 7 Buy Ratings
Consensus Rating:Buy (Score: 2.88)
Consensus Price Target: $67.67 (33.60% upside)
Consensus Price Target History for Portola Pharmaceuticals (NASDAQ:PTLA)
Price Target History for Portola Pharmaceuticals (NASDAQ:PTLA)
Analysts' Ratings History for Portola Pharmaceuticals (NASDAQ:PTLA)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/6/2017Oppenheimer Holdings, Inc.Set Price TargetBuy$80.00N/AView Rating Details
10/6/2017Morgan StanleyReiterated RatingOverweight$75.00 -> $81.00N/AView Rating Details
8/23/2017Credit Suisse GroupUpgradeNeutral -> Outperform$70.00HighView Rating Details
6/26/2017Cowen and CompanyBoost Price TargetOutperform$45.00 -> $70.00HighView Rating Details
6/26/2017William BlairReiterated RatingOutperformHighView Rating Details
6/26/2017Citigroup Inc.Boost Price TargetBuy$51.00 -> $78.00MediumView Rating Details
2/24/2017CIBCUpgradeMarket Perform -> OutperformN/AView Rating Details
1/11/2017Goldman Sachs Group, Inc. (The)Reiterated RatingNeutral$22.00 -> $27.00N/AView Rating Details
(Data available from 10/20/2015 forward)

Earnings

Earnings History for Portola Pharmaceuticals (NASDAQ:PTLA)
Earnings by Quarter for Portola Pharmaceuticals (NASDAQ:PTLA)
Earnings History by Quarter for Portola Pharmaceuticals (NASDAQ PTLA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/6/2017($1.49)N/AView Earnings Details
8/9/2017Q2 2017($1.10)($1.22)$4.28 million$3.79 millionViewListenView Earnings Details
5/8/2017Q1 2017($1.20)($0.74)$4.21 million$5.12 millionViewListenView Earnings Details
2/28/2017Q4 2016($1.12)($0.95)$3.98 million$13.70 millionViewListenView Earnings Details
11/7/2016Q3($1.10)($1.64)$4.10 million$9.30 millionViewListenView Earnings Details
8/9/2016Q216($1.20)($1.02)$4.38 million$4.23 millionViewListenView Earnings Details
5/5/2016Q1($1.06)($1.15)$7.91 million$8.30 millionViewListenView Earnings Details
2/26/2016Q415($1.12)($1.23)$2.43 million$4.40 millionViewListenView Earnings Details
8/4/2015Q215($1.07)($1.12)$2.30 million$2.39 millionViewListenView Earnings Details
5/6/2015Q115($1.09)($0.95)$2.60 million$2.36 millionViewListenView Earnings Details
3/2/2015Q414($0.90)($0.82)$2.40 million$2.41 millionViewListenView Earnings Details
11/10/2014Q314($0.92)($0.86)$2.73 million$2.40 millionViewListenView Earnings Details
8/6/2014Q214($0.79)($0.76)$2.44 million$2.42 billionViewListenView Earnings Details
5/12/2014Q114($0.72)($0.75)$1.81 million$2.40 millionViewListenView Earnings Details
2/27/2014Q4($0.57)($0.63)$2.17 million$2.10 millionViewListenView Earnings Details
8/15/2013($0.72)($1.47)ViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Portola Pharmaceuticals (NASDAQ:PTLA)
2017 EPS Consensus Estimate: ($5.40)
2018 EPS Consensus Estimate: ($2.56)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($1.30)($1.12)($1.21)
Q2 20172($1.24)($1.06)($1.15)
Q3 20172($1.68)($1.45)($1.57)
Q4 20172($1.49)($1.45)($1.47)
Q1 20181($1.08)($1.08)($1.08)
Q2 20181($0.86)($0.86)($0.86)
Q3 20181($0.47)($0.47)($0.47)
Q4 20181($0.15)($0.15)($0.15)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Portola Pharmaceuticals (NASDAQ:PTLA)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Portola Pharmaceuticals (NASDAQ:PTLA)
Insider Ownership Percentage: 4.90%
Institutional Ownership Percentage: 85.06%
Insider Trades by Quarter for Portola Pharmaceuticals (NASDAQ:PTLA)
Institutional Ownership by Quarter for Portola Pharmaceuticals (NASDAQ:PTLA)
Insider Trades by Quarter for Portola Pharmaceuticals (NASDAQ:PTLA)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/18/2017John T. CurnutteInsiderSell10,000$65.00$650,000.00View SEC Filing  
7/18/2017Tao FuEVPSell5,812$65.00$377,780.00View SEC Filing  
7/11/2017Mardi DierVPSell23,350$60.00$1,401,000.00View SEC Filing  
6/28/2017William LisCEOSell269,299$55.43$14,927,243.57View SEC Filing  
6/27/2017Mardi DierVPSell93,392$55.46$5,179,520.32View SEC Filing  
6/26/2017John T. CurnutteInsiderSell60,000$57.88$3,472,800.00View SEC Filing  
6/26/2017Tao FuEVPSell7,000$57.14$399,980.00View SEC Filing  
6/23/2017Charles J. HomcyDirectorSell120,803$53.06$6,409,807.18View SEC Filing  
6/1/2017(Mauritius) Pte Ltd MaxwellMajor ShareholderSell1,700,000$34.40$58,480,000.00View SEC Filing  
6/1/2017Jeffrey W BirdDirectorBuy119,442$31.85$3,804,227.70View SEC Filing  
4/11/2017William LisCEOSell6,750$36.06$243,405.00View SEC Filing  
4/10/2017Tao FuEVPSell1,097$36.97$40,556.09View SEC Filing  
3/15/2017Charles J. HomcyDirectorSell50,000$40.06$2,003,000.00View SEC Filing  
3/15/2017Mardi DierVPSell10,235$40.02$409,604.70View SEC Filing  
5/2/2016William LisCEOSell5,675$23.86$135,405.50View SEC Filing  
12/9/2015Fullerton Management Pte LtdMajor ShareholderBuy750,000$48.00$36,000,000.00View SEC Filing  
9/18/2015Charles J. HomcyDirectorSell40,067$56.25$2,253,768.75View SEC Filing  
9/18/2015Mardi DierCFOSell8,912$55.00$490,160.00View SEC Filing  
7/15/2015John T CurnutteEVPSell10,000$50.00$500,000.00View SEC Filing  
7/15/2015William LisCEOSell50,000$50.00$2,500,000.00View SEC Filing  
7/13/2015Charles J HomcyDirectorSell50,000$48.00$2,400,000.00View SEC Filing  
7/2/2015William LisCEOSell15,000$45.60$684,000.00View SEC Filing  
7/1/2015William LisCEOSell30,000$45.01$1,350,300.00View SEC Filing  
6/30/2015William LisCEOSell15,000$44.48$667,200.00View SEC Filing  
6/29/2015Charles J HomcyDirectorSell100,000$43.78$4,378,000.00View SEC Filing  
6/22/2015John T CurnutteEVPSell10,000$47.50$475,000.00View SEC Filing  
6/16/2015John T CurnutteEVPSell10,000$45.00$450,000.00View SEC Filing  
6/8/2015Mardi DierCFOSell16,119$43.00$693,117.00View SEC Filing  
5/29/2015John T CurnutteEVPSell10,000$42.50$425,000.00View SEC Filing  
5/28/2015John T CurnutteEVPSell10,000$40.30$403,000.00View SEC Filing  
5/27/2015Mardi DierCFOSell6,076$41.00$249,116.00View SEC Filing  
5/12/2015Mardi DierCFOSell13,290$37.88$503,425.20View SEC Filing  
5/11/2015Hollings RentonDirectorSell10,520$38.33$403,231.60View SEC Filing  
5/11/2015Mardi DierCFOSell13,674$38.21$522,483.54View SEC Filing  
4/30/2015William LisCEOSell45,000$35.60$1,602,000.00View SEC Filing  
2/23/2015Charles J HomcyDirectorSell20,000$40.00$800,000.00View SEC Filing  
2/23/2015John T CurnutteEVPSell10,000$40.00$400,000.00View SEC Filing  
2/23/2015Mardi DierCFOSell5,692$39.95$227,395.40View SEC Filing  
2/18/2015John T CurnutteEVPSell10,000$37.50$375,000.00View SEC Filing  
2/17/2015Charles J HomcyDirectorSell20,000$36.00$720,000.00View SEC Filing  
2/17/2015John T CurnutteEVPSell10,000$35.00$350,000.00View SEC Filing  
2/13/2015Charles J HomcyDirectorSell20,000$34.05$681,000.00View SEC Filing  
2/13/2015John T CurnutteEVPSell10,000$32.50$325,000.00View SEC Filing  
1/28/2015Charles J HomcyDirectorSell19,700$30.00$591,000.00View SEC Filing  
1/20/2015William LisCEOSell20,000$27.32$546,400.00View SEC Filing  
1/16/2015William LisCEOSell20,000$26.94$538,800.00View SEC Filing  
11/25/2014Mardi DierCFOSell1,118$28.23$31,561.14View SEC Filing  
11/20/2014William LisCEOSell40,000$26.95$1,078,000.00View SEC Filing  
11/17/2014William LisCEOSell30,000$26.69$800,700.00View SEC Filing  
10/8/2014(Mauritius) Pte Ltd MaxwellMajor ShareholderBuy1,600,000$26.00$41,600,000.00View SEC Filing  
8/25/2014Mardi DierCFOSell5,000$26.26$131,300.00View SEC Filing  
7/25/2014Mardi DierCFOSell5,000$24.11$120,550.00View SEC Filing  
7/3/2014William LisCEOSell30,000$30.41$912,300.00View SEC Filing  
6/30/2014William LisCEOSell10,000$29.23$292,300.00View SEC Filing  
6/25/2014Mardi DierCFOSell5,000$28.52$142,600.00View SEC Filing  
6/18/2014John T CurnutteEVPSell30,000$28.33$849,900.00View SEC Filing  
6/18/2014Mardi DierCFOSell3,706$29.95$110,994.70View SEC Filing  
6/16/2014John T CurnutteEVPSell10,000$26.00$260,000.00View SEC Filing  
6/10/2014Nicholas GalakatosDirectorSell1,369$23.36$31,979.84View SEC Filing  
5/29/2014Mardi DierCFOSell5,000$23.00$115,000.00View SEC Filing  
5/27/2014William LisCEOSell30,000$20.83$624,900.00View SEC Filing  
5/21/2014William LisCEOSell10,000$19.87$198,700.00View SEC Filing  
5/16/2014Jean Jacques BienaimeDirectorSell1,000$22.03$22,030.00View SEC Filing  
4/25/2014Mardi DierCFOSell5,000$24.14$120,700.00View SEC Filing  
3/25/2014Mardi DierCFOSell5,000$25.69$128,450.00View SEC Filing  
10/22/2013Charles J HomcyDirectorSell95,962$23.75$2,279,097.50View SEC Filing  
5/28/2013(Mauritius) Pte Ltd MaxwellMajor ShareholderBuy700,000$14.50$10,150,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Portola Pharmaceuticals (NASDAQ:PTLA)
Latest Headlines for Portola Pharmaceuticals (NASDAQ:PTLA)
Source:
DateHeadline
americanbankingnews.com logoPortola Pharmaceuticals, Inc. (PTLA) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - October 19 at 6:50 PM
americanbankingnews.com logoPortola Pharmaceuticals, Inc. Forecasted to Earn FY2017 Earnings of ($4.86) Per Share (PTLA)
www.americanbankingnews.com - October 13 at 7:54 AM
globenewswire.com logoPortola Pharmaceuticals Supports 2017 World Thrombosis Day Campaign to Raise Awareness about the Persistent ... - GlobeNewswire (press release)
globenewswire.com - October 12 at 8:38 AM
globenewswire.com logoPortola Pharmaceuticals Supports 2017 World Thrombosis Day Campaign to Raise Awareness about the Persistent ... - GlobeNewswire (press release)
globenewswire.com - October 12 at 8:38 AM
finance.yahoo.com logoPortola Pharmaceuticals Supports 2017 World Thrombosis Day Campaign to Raise Awareness about the Persistent Risk of Blood Clots
finance.yahoo.com - October 12 at 8:38 AM
finance.yahoo.com logoPortola Pharmaceuticals Supports 2017 World Thrombosis Day Campaign to Raise Awareness about the Persistent Risk of Blood Clots
finance.yahoo.com - October 12 at 8:38 AM
americanbankingnews.com logoReviewing Portola Pharmaceuticals (PTLA) and Its Rivals
www.americanbankingnews.com - October 10 at 9:06 AM
americanbankingnews.com logoPortola Pharmaceuticals, Inc. (PTLA) PT Set at $80.00 by Oppenheimer Holdings, Inc.
www.americanbankingnews.com - October 6 at 9:08 PM
americanbankingnews.com logoPortola Pharmaceuticals, Inc. (PTLA) Price Target Raised to $81.00
www.americanbankingnews.com - October 6 at 11:02 AM
americanbankingnews.com logoFY2017 EPS Estimates for Portola Pharmaceuticals, Inc. (PTLA) Lifted by Analyst
www.americanbankingnews.com - October 6 at 7:58 AM
americanbankingnews.com logo$2.42 Million in Sales Expected for Portola Pharmaceuticals, Inc. (PTLA) This Quarter
www.americanbankingnews.com - October 4 at 3:18 PM
americanbankingnews.com logo Brokerages Anticipate Portola Pharmaceuticals, Inc. (PTLA) to Announce -$1.51 EPS
www.americanbankingnews.com - October 2 at 12:22 PM
benzinga.com logoJim Cramer Advises His Viewers On Southwest Airlines And General Electric - Benzinga
www.benzinga.com - September 27 at 8:21 AM
finance.yahoo.com logoCramer's lightning round: Portola's no one-trick pony
finance.yahoo.com - September 27 at 8:20 AM
prnewswire.com logoTechnical Reports on Biotech Equities -- Opko Health, Otonomy, Pacific Biosciences of California, and Portola Pharma - PR Newswire (press release)
www.prnewswire.com - September 25 at 9:40 AM
americanbankingnews.com logoPortola Pharmaceuticals, Inc. (PTLA) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - September 24 at 6:42 PM
seekingalpha.com logoPortola - A High-Risk, High-Return Investment Opportunity - Seeking Alpha
seekingalpha.com - September 23 at 5:53 AM
seekingalpha.com logoExpect A Slow Bleed With Portola Pharma
seekingalpha.com - September 22 at 7:46 PM
americanbankingnews.com logoResearch Analysts Set Expectations for Portola Pharmaceuticals, Inc.'s Q3 2017 Earnings (PTLA)
www.americanbankingnews.com - September 22 at 6:36 AM
americanbankingnews.com logoWilliam Blair Weighs in on Portola Pharmaceuticals, Inc.'s FY2020 Earnings (PTLA)
www.americanbankingnews.com - September 21 at 3:56 PM
streetinsider.com logoPortola Pharma (PTLA) Weakness Tied to Earlier Article in STAT - StreetInsider.com
www.streetinsider.com - September 20 at 8:02 AM
finance.yahoo.com logoToday's Research Reports on Trending Tickers: Portola Pharmaceuticals and Synchronoss Technologies
finance.yahoo.com - September 20 at 8:02 AM
americanbankingnews.com logo Brokerages Expect Portola Pharmaceuticals, Inc. (PTLA) Will Announce Quarterly Sales of $2.42 Million
www.americanbankingnews.com - September 15 at 5:20 AM
finance.yahoo.com logoPortola Shares Lower After Pricing Stock Offering - Biotech Movers
finance.yahoo.com - September 14 at 9:31 AM
finance.yahoo.com logoPortola Announces Pricing of Public Offering of Common Stock
finance.yahoo.com - September 13 at 8:01 AM
rttnews.com logoPortola Pharmaceuticals Inc. (PTLA) Is Falling After Offering Announcement
www.rttnews.com - September 12 at 8:54 AM
finance.yahoo.com logoPortola Pharmaceuticals Announces Proposed Offering of Common Stock
finance.yahoo.com - September 12 at 8:54 AM
businesswire.com logoSHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Portola ...
www.businesswire.com - September 8 at 7:19 AM
prnewswire.com logoSHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Portola Pharmaceuticals Inc ... - PR Newswire (press release)
www.prnewswire.com - September 7 at 7:55 AM
finance.yahoo.com logoPortola Pharmaceuticals to Present at the 2017 Morgan Stanley Global Healthcare Conference
finance.yahoo.com - September 7 at 7:55 AM
finance.yahoo.com logoToday's Research Reports on Trending Tickers: Pulmatrix Inc. and Portola Pharmaceuticals Inc.
finance.yahoo.com - September 7 at 7:55 AM
finance.yahoo.com logoSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Portola Pharmaceuticals Inc. - PTLA
finance.yahoo.com - September 7 at 7:55 AM
finance.yahoo.com logoSHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Portola Pharmaceuticals Inc. (PTLA)
finance.yahoo.com - September 7 at 7:55 AM
finance.yahoo.com logoSHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Portola Pharmaceuticals, Inc.
finance.yahoo.com - September 7 at 7:55 AM
americanbankingnews.com logoPortola Pharmaceuticals, Inc. (PTLA) Rating Reiterated by Oppenheimer Holdings, Inc.
www.americanbankingnews.com - September 6 at 3:20 PM
finance.yahoo.com logoReminder: Portola Pharmaceuticals to Host Webcast and Conference Call Today, Tuesday, Sept. 5 to Provide Further Details on Bevyxxa® (betrixaban) Launch
finance.yahoo.com - September 5 at 3:52 PM
americanbankingnews.com logoPortola Pharmaceuticals, Inc. (PTLA) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - August 30 at 6:42 PM
finance.yahoo.com logoETFs with exposure to Portola Pharmaceuticals, Inc. : August 25, 2017
finance.yahoo.com - August 26 at 8:32 AM
finance.yahoo.com logoPortola Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : PTLA-US : August 25, 2017
finance.yahoo.com - August 25 at 10:22 AM
americanbankingnews.com logoPortola Pharmaceuticals, Inc. (PTLA) Upgraded by Credit Suisse Group to "Outperform"
www.americanbankingnews.com - August 23 at 9:42 PM
nasdaq.com logoPortola Pharmaceuticals Announces Upcoming Data Presentations on Betrixaban ...
www.nasdaq.com - August 22 at 6:05 AM
finance.yahoo.com logoPortola Pharmaceuticals Announces Upcoming Data Presentations on Betrixaban and Andexanet Alfa at the European Society of Cardiology (ESC) Congress 2017
finance.yahoo.com - August 22 at 6:04 AM
americanbankingnews.com logoWilliam Blair Brokers Reduce Earnings Estimates for Portola Pharmaceuticals, Inc. (PTLA)
www.americanbankingnews.com - August 18 at 7:52 AM
nasdaq.com logoPortola Pharmaceuticals Becomes Oversold (PTLA)
www.nasdaq.com - August 17 at 8:26 PM
americanbankingnews.com logoPortola Pharmaceuticals, Inc. (PTLA) to Post FY2019 Earnings of $1.02 Per Share, William Blair Forecasts
www.americanbankingnews.com - August 17 at 3:38 PM
streetinsider.com logoPortola Pharma (PTLA) Reports AndexXa (Andexanet Alfa) Biologics License Application Resubmission Accepted for ... - StreetInsider.com
www.streetinsider.com - August 17 at 3:24 PM
nasdaq.com logoFDA Accepts Portola's (PTLA) BLA Resubmission for AndexXa - Nasdaq
www.nasdaq.com - August 17 at 3:24 PM
finance.yahoo.com logoFeatured Company News - Portola Pharmaceuticals' AndexXa(R) Biologics License Application Resubmission Accepted for Review by US FDA
finance.yahoo.com - August 17 at 3:24 PM
finance.yahoo.com logoFDA Accepts Portola's (PTLA) BLA Resubmission for AndexXa
finance.yahoo.com - August 17 at 3:24 PM
finance.yahoo.com logoPortola Pharmaceuticals Inc
finance.yahoo.com - August 17 at 7:04 AM

Social

Chart

Portola Pharmaceuticals (PTLA) Chart for Friday, October, 20, 2017

This page was last updated on 10/20/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.